BioCryst Pharmaceuticals, Inc.
Every calculator, already run for BCRX
Open the full toolkit →You have the numbers on BCRX. Get the argument.
A written report on which of these readings actually decide the outcome for BioCryst Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering BCRXAnalyst Price Target Disagreement for BioCryst Pharmaceuticals, Inc.
Wall Street's bull case implies +229% from the current price; the bear case implies +23%. A 205% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX…
BCRX — frequently asked
Is BCRX a buy right now?
Wall Street's consensus rating on BioCryst Pharmaceuticals, Inc. is Strong Buy across 11 analysts, with a mean price target of $20.82 (+114% vs. the current $9.74). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BCRX overvalued?
BCRX trades at — trailing earnings, against a DCF fair value of $45 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BCRX's next earnings date?
BioCryst Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 2, 2026. A full BCRX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for BioCryst Pharmaceuticals, Inc.?
Analysts covering BioCryst Pharmaceuticals, Inc. (BCRX) range from a bear-case target of $12.00 to a bull-case high of $32.00, with a mean consensus target of $20.82 across 11 analysts. The spread of $20.00 (205% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare BioCryst Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For BioCryst Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BCRX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on BioCryst Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.